Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantageMarco Ladetto, Corrado Tarella, Federica De Marco et al.|Blood|2008Cited by 253
ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)Michele Ghielmini, Markus Raderer, Umberto Vitolo et al.|Annals of Oncology|2012Cited by 218
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With LymphomaCorrado Tarella, Alessandro Rambaldi, Roberto Passera et al.|Journal of Clinical Oncology|2010Cited by 167
Genetic and phenotypic attributes of splenic marginal zone lymphomaFerdinando Bonfiglio, Estella Matutes, Giorgio Inghirami et al.|Blood|2021Cited by 96
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Antonio Palumbo, Valeria Magarotto et al.|Blood|2013Cited by 82